In this online, self-learning activity:
Short bowel syndrome (SBS) is a condition in which a patient exhibits malabsorption-induced diarrhea, dehydration, electrolyte imbalances, and malnutrition due to decreased nutrient absorption that results from extensive surgical resection of the intestine or congenital defects. It is a form of intestinal failure (IF), which is defined as a need for supplementary parenteral or enteral nutrition when intestinal function is insufficient to meet the body’s nutritional requirements. The prevalence of SBS has been estimated to be 3–4 per million patients in the U.S. based on home parenteral nutrition (HPN) data, and in adults undergoing intestinal resection, SBS is estimated to occur in 15% of adult patients, with 75% of patients undergoing a single massive resection.
The following healthcare professionals: gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in gastroenterology; and any other healthcare professionals with an interest in or who clinically encounter patients with short bowel syndrome.
This activity is supported by an educational grant from Shire.
Release Date: May 02, 2019 -- Expiration Date: May 02, 2021
Faculty: Douglas Nguyen, MD
Introduction and disclosures
Pathophysiology, diagnosis, and complications
· Risk factors, diagnosis
· Parenteral Nutrition-Related Complications
· Bowel Anatomy-Related Complications
Short bowel syndrome management
· Nutrition therapy (acute, transition, and chronic management): diet, EN, PN, adjunct pharmacotherapy for fluid loss
· Teduglutide: role in therapy, dosing and administration
· Vitamin D supplementation: serum 25-OHD and BMD monitoring
· Autologous surgical reconstruction
· Patient and provider education
· Practice Gaps
By the end of the session the participant will be able to:
ACCME Activity #201226478ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty & Planner Disclosures:
Douglas Nguyen, M.D., Associate Clinical Professor of Medicine, Univ of California, Irvine, discloses that he is a consultant and on speaker's bureau for Abbvie, Janseen, Nestle, and Gilead.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This activity is supported by an educational grant from Shire.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Ulcerative Colitis (UC): Optimizing Pharmacotherapeutic Management Strategies
Employing biosimilars in the treatment of inflammatory health conditions: How to and should I?
Pediatric Crohn's disease: Therapeutic updates and optimizing treatment
Ulcerative Colitis: Updates from the DDW 2019 Annual Meeting